Figure 1. Evidence of rapid tumor regrowth following bevacizumab cessation, within 1 month, with accelerated kinetics in patient 2 (A) before first BV treatment, (B) during first BV treatment, before surgery, (C) 1 month after colon and liver surgery and (D) during second BV treatment, after surgery.
Ré sumé : La chimiothé rapie des cancers colorectaux a é té profondé -ment modifié e ces derniè res anné es. Alors mê me que la place respective de l'irinoté can et de l'oxaliplatine n'é tait pas complè tement dé finie, les thé rapies ciblé es sont arrivé es. De nombreuses questions de straté gie thé rapeutique restent non ré solues, mais des informations scientifiques ré centes permettent d'y voir un peu plus clair au quotidien pour traiter les malades. Le but de cet article est de faire le point sur ces donné es ré centes dans un domaine en permanente é volution.Mots clé s : Cancer colorectal -Chimiothé rapie -Thé rapies ciblé esOxaliplatine -Irinoté can -Bé vacizumab -Cé tuximab -Panitumumab Developments in chemotherapy treatment of metastatic colorectal cancer Abstract: Chemotherapy of colorectal cancer has been dramatically modified during the last 10 years. Before the roles of oxaliplatin and irinotecan had been satisfactorily evaluated, targeted therapies appeared in the field of treatment for these patients. Numerous questions remain unanswered. However, recent data is helping to clarify matters concerning the day to day treatment of such patients. Clearly it is time to evaluate these recent studies and that is the aim of this article.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.